The Rhinosinusitis drugs in development market research report provides comprehensive information on the therapeutics under development for Rhinosinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rhinosinusitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rhinosinusitis and features dormant and discontinued products.
GlobalData tracks 38 drugs in development for Rhinosinusitis by 34 companies/universities/institutes. The top development phase for Rhinosinusitis is phase ii with 13 drugs in that stage. The Rhinosinusitis pipeline has 38 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Rhinosinusitis pipeline products market are: Chia Tai Tianqing Pharmaceutical Group, SaNOtize Research and Development and ABT Innovations.
The key targets in the Rhinosinusitis pipeline products market include Interleukin 4 Receptor Subunit Alpha, Thymic Stromal Lymphopoietin, and Interleukin 13.
The key mechanisms of action in the Rhinosinusitis pipeline product include Interleukin 4 Receptor Subunit Alpha Antagonist with seven drugs in Pre-Registration. The Rhinosinusitis pipeline products include eight routes of administration with the top ROA being Subcutaneous and four key molecule types in the Rhinosinusitis pipeline products market including Monoclonal Antibody, and Small Molecule.
Rhinosinusitis overview
Rhinosinusitis is a condition that affects the nasal and sinus mucosa, causing inflammation and symptoms such as nasal congestion, discharge, pain, and loss of smell. It can be classified into acute or chronic, depending on the duration of the illness. Acute rhinosinusitis usually lasts less than four weeks and is often caused by viral or bacterial infections. Chronic rhinosinusitis lasts more than 12 weeks and is often associated with allergies, nasal polyps, deviated septum, or fungal infections. Rhinosinusitis can be diagnosed by history, physical examination, and sometimes by nasal or sputum culture or CT scan. Treatment options include pain relievers, decongestants, nasal irrigation, topical steroids, antibiotics, and surgery in some cases. Rhinosinusitis can affect the quality of life and lead to complications such as sleep apnea and orbital or intracranial infections if left untreated.
For a complete picture of Rhinosinusitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
